OD2-2 Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
CK Lee, H.J. Chon, J. Chon, M.A. Lee et autres
HER2 over-expression/amplification, which accounts for roughly 15% of total biliary tract cancer (BTC) patients, has been identified as a druggable molecular target by recent genomic profilings. Trastuzumab is a humanized monoclonal antibody against HER2 that has been shown to be effective in …
kr (code pays fourni par la source)
2 citations
ESMO Open